Evaluate

September 17, 2019

Roche and Celgene set for battle in acute myelogenous leukaemia

Last week's pivotal trial success could give Celgene a second AML drug, setting up a battle against Roche's Venclexta and idasanutlin.

November 17, 2016

Gilead’s myelofibrosis stumble leaves way clear for Jakafi

August 12, 2016

Snippet roundup: Lilly pill slips, Mek inhibitors reach limit, Myriad buys

February 16, 2016

Zealand plays catch-up with Shire in short bowel syndrome

August 18, 2015

Therapeutic focus – Cachexia research enlivened by cancer asset chase

May 29, 2015

Heron works Magic to conjure trial win

November 25, 2014

Interview – Oncology advances leave a niche for Helsinn

September 27, 2014

Esmo – Cachexia progress at last, but watch the diabetes

August 18, 2014

A defensive Chugai move could still make sense for Roche